{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:46:17Z","timestamp":1772120777861,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.diabet.2012.10.005","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T02:49:44Z","timestamp":1354934984000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Management of hyperglycaemia in Cushing's disease: Experts\u2019 proposals on the use of pasireotide"],"prefix":"10.1016","volume":"39","author":[{"given":"Y.","family":"Reznik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Brue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cortet-Rudelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tabarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bisot-Locard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2012.10.005_bib0005","unstructured":"Syndrome de Cushing, protocole national de diagnostic et de soins, HAS, septembre 2008."},{"key":"10.1016\/j.diabet.2012.10.005_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1750-1172-7-41","article-title":"Cushing's disease","volume":"7","author":"Castinetti","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.diabet.2012.10.005_bib0015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","article-title":"Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma","volume":"92","author":"Dekkers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0025","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/jc.2005-1058","article-title":"Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission","volume":"91","author":"Lindsay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2012.10.005_bib0035","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1530\/eje.1.02350","article-title":"Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas","volume":"156","author":"van der Hoek","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2012.10.005_bib0040","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2012.10.005_bib0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0050","first-page":"P252","article-title":"Initial management and complications of Cushing disease (CD): a French multicenter study of 437 patients","volume":"26","author":"Baudry","year":"2011","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.diabet.2012.10.005_bib0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2012.10.005_bib0060","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.diabet.2012.10.005_bib0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11102-005-1172-7","article-title":"Cardiovascular risk in Cushing's syndrome","volume":"7","author":"Arnaldi","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.diabet.2012.10.005_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.diabet.2012.10.005_bib0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2012.10.005_bib0080","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2012.10.005_bib0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-955096","article-title":"Preserved GLP-1 effects in a diabetic patient with Cushing's disease","volume":"115","author":"Ritzel","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabet.2012.10.005_bib0095","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1210\/jc.2008-1297","article-title":"Changes in adenosine 5\u2032-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome","volume":"93","author":"Kola","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2012.10.005_bib0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","article-title":"Pathophysiology of diabetes mellitus in Cushing's syndrome","volume":"92","author":"Pivonello","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.diabet.2012.10.005_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/jcem-57-3-529","article-title":"Insulin resistance in Cushing's syndrome","volume":"57","author":"Nosadini","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2012.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.2010-2729","article-title":"Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD","volume":"96","author":"Burt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0120","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0125","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","article-title":"Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5","volume":"57","author":"Zambre","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.diabet.2012.10.005_bib0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets","volume":"92","author":"Singh","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/JOE-11-0224","article-title":"Effects of somatostatin analogs on glucose homeostasis in rats","volume":"212","author":"Schmid","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2012.10.005_bib0140","first-page":"P26","article-title":"Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers","volume":"26","author":"Henry","year":"2011","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.diabet.2012.10.005_bib0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2012.10.005_bib0150","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes-2012. Diabetes Care 2012;35 (Suppl. 1):S11\u2013S63.","DOI":"10.2337\/dc12-s011"},{"key":"10.1016\/j.diabet.2012.10.005_bib0155","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363612002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363612002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:54:54Z","timestamp":1761130494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363612002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1262363612002017"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2012.10.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717967964.793490678","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717967964.793467626","asserted-by":"object"}]},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hyperglycaemia in Cushing's disease: Experts\u2019 proposals on the use of pasireotide","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2012.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}